PUBLIC COMPANY
saveDAIICHI SANKYO
USupdated 5mo ago
community read0 votes
pipeline
0
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(0)
no pipeline products on record
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase2A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
- phase3A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events
- phase3Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
- phase1A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors
- phase3HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy
- phase1First-in-Human Trial of DS1025a in Participants With Advanced Solid Tumors
- phase2A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies
- phase3Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
🐶 Hiring Signal
News
- Summit partners with AstraZeneca and Daiichi; Eccogene earns $50M milestonePlus news about Regeneron. Summit Therapeutics to test cancer drug with Datroway: The biotech agreed to partner with AstraZeneca and Daiichi Sankyo on a clinical trial collaboration, testing its Tr…endpoints · 1d ago
- Merck inks up to $2.13B deal to dine with SciBrunch, gain rights to preclinical KRAS inhibitorMerck continues to diversify its cancer efforts as the clock ticks down on Keytruda’s patent, picking up rights to a preclinical oncology asset in a deal that could exceed $2 billion.biospace · 5d ago
- STAT+: Pharmalittle: We’re reading about GLP-1s becoming lifestyle drugs, a setback for Merck and Daiichi, and moreOnce promoted as tools to address obesity as a medical issue, GLP-1 drugs are increasingly being marketed as a way to look and feel betterstat · 5d ago
- Merck, Daiichi end plans to seek speedy approval of lung cancer ADCThe FDA indicated that the data generated so far wouldn’t support an accelerated clearance of “I-DXd,” a setback that erases an edge Merck and Daiichi had over multiple fast-moving competitors.biopharma_dive · 5d ago
- Merck, Daiichi Sankyo retract accelerated approval request for lung cancer ADCMerck and Daiichi Sankyo’s withdrawal of an accelerated approval request for the antibody-drug conjugate ifinatamab deruxtecan is a “net positive” for rivals like GSK and Roche, according to RBC Ca…biospace · 6d ago
- Merck, Daiichi scrap FDA application for B7-H3 ADC in lung cancerIn yet another setback to the Merck and Daiichi Sankyo partnership, the companies said they have pulled their FDA accelerated approval application for an antibody-drug conjugate (ADC) in certain sm…endpoints · 6d ago
- Merck, Daiichi pull lung cancer filing after FDA pushback deals another blow to $4B dealDaiichi Sankyo and Merck & Co. have withdrawn an antibody-drug conjugate (ADC) filing after the FDA said they lacked the data for accelerated approval in a lung cancer population.fiercebiotech · 6d ago
- Roche, MediLink notch phase 3 lung cancer win but trail GSK on cross-trial survivalMediLink has reported phase 3 results on a Roche-partnered antibody-drug conjugate. The small-cell lung cancer trial hit its primary endpoint, although the B7-H3-directed ADC’s median overall survi…fiercebiotech · 20d ago
- BioNTech sets survival standard in hard-to-treat cancer ahead of pivotal readoutBioNTech has linked gotistobart to a median overall survival of 18.5 months in relapsed lung cancer patients, adding to evidence that the anti-CTLA-4 antibody is better than the standard of care.fiercebiotech · 23d ago
- GSK’s Hansoh-partnered ADC lays down marker for lung cancer scrap with MerckGSK’s risvutatug rezetecan has achieved a median overall survival of 18.5 months in a phase 3 trial, painting the antibody-drug conjugate as a threat to Amgen and Merck & Co. in the lung cancer field.fiercebiotech · 23d ago
comments(0)
5-min edit window · permanent after that